ERBB2 and invasive ductal breast carcinoma: Clinically, most participants had Stage I disease (67.9%, n = 19) and were diagnosed with invasive ductal carcinoma (82.1%, n = 23) and ER/PR-positive, HER2-negative tumors (75%, n = 21).